Amyl Therapeutics closes €18.3 million Series A financing to develop novel therapies for Amyloidosis
LIEGE, Belgium – June 3, 2021: Amyl Therapeutics (‘Amyl’), a preclinical stage biotechnology company developing its amyloid fibrils specific technology platform named ClariTY for the treatment of all forms of Amyloidosis, today announced that it has successfully closed a €18.3 million Series A financing. The funding round comprises €8.6 million in equity led by Noshaq – a […]